S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Affimed Stock Forecast, Price & News

-0.03 (-0.51 %)
(As of 10/15/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume495,317 shs
Average Volume2.00 million shs
Market Capitalization$580.88 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AFMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Affimed logo

About Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA. The company was founded in 2000 and is headquartered in Heidelberg, Germany.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$32.39 million
Book Value
$0.84 per share


Net Income
$-47.25 million




Market Cap
$580.88 million
Next Earnings Date
11/9/2021 (Estimated)


Overall MarketRank

2.14 out of 5 stars

Medical Sector

432nd out of 1,361 stocks

Pharmaceutical Preparations Industry

197th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Affimed (NASDAQ:AFMD) Frequently Asked Questions

Is Affimed a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed
or view top-rated stocks.

What stocks does MarketBeat like better than Affimed?

Wall Street analysts have given Affimed a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Affimed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Affimed

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its quarterly earnings results on Tuesday, September, 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.10. The biopharmaceutical company earned $11.70 million during the quarter, compared to the consensus estimate of $13.57 million. Affimed had a negative trailing twelve-month return on equity of 34.91% and a negative net margin of 91.76%. During the same period in the prior year, the company earned ($0.18) earnings per share.
View Affimed's earnings history

How has Affimed's stock price been impacted by Coronavirus (COVID-19)?

Affimed's stock was trading at $1.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AFMD stock has increased by 224.7% and is now trading at $5.91.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AFMD?

5 Wall Street analysts have issued 1-year target prices for Affimed's shares. Their forecasts range from $12.00 to $15.00. On average, they expect Affimed's share price to reach $13.80 in the next twelve months. This suggests a possible upside of 133.5% from the stock's current price.
View analysts' price targets for Affimed
or view top-rated stocks among Wall Street analysts.

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Adolf Hoess, Chief Executive Officer
  • Wolfgang Fischer, Chief Operating Officer
  • Angus W. Smith, Chief Financial Officer
  • Andreas Harstrick, Chief Medical Officer
  • Arndt Schottelius, Chief Scientific Officer

What other stocks do shareholders of Affimed own?

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Who are Affimed's major shareholders?

Affimed's stock is owned by a variety of retail and institutional investors. Top institutional investors include Harbor Investment Advisory LLC (0.22%).

Which institutional investors are buying Affimed stock?

AFMD stock was purchased by a variety of institutional investors in the last quarter, including Harbor Investment Advisory LLC.

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $5.91.

How much money does Affimed make?

Affimed has a market capitalization of $580.88 million and generates $32.39 million in revenue each year. The biopharmaceutical company earns $-47.25 million in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does Affimed have?

Affimed employs 158 workers across the globe.

What is Affimed's official website?

The official website for Affimed is www.affimed.com.

Where are Affimed's headquarters?

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The biopharmaceutical company can be reached via phone at 496221674360 or via email at [email protected].

This page was last updated on 10/17/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.